MX2022014331A - Metodos y composiciones para el tratamiento de trastornos epilepticos. - Google Patents

Metodos y composiciones para el tratamiento de trastornos epilepticos.

Info

Publication number
MX2022014331A
MX2022014331A MX2022014331A MX2022014331A MX2022014331A MX 2022014331 A MX2022014331 A MX 2022014331A MX 2022014331 A MX2022014331 A MX 2022014331A MX 2022014331 A MX2022014331 A MX 2022014331A MX 2022014331 A MX2022014331 A MX 2022014331A
Authority
MX
Mexico
Prior art keywords
treatment
compositions
methods
epileptic disorders
epileptic
Prior art date
Application number
MX2022014331A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61159951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022014331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2022014331A publication Critical patent/MX2022014331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Uso demoduladores alostéricos y/o gaboxadol para el tratamiento de trastornos epilépticos en un sujeto que lo necesita.
MX2022014331A 2016-08-11 2019-02-08 Metodos y composiciones para el tratamiento de trastornos epilepticos. MX2022014331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662373589P 2016-08-11 2016-08-11
US201762490293P 2017-04-26 2017-04-26

Publications (1)

Publication Number Publication Date
MX2022014331A true MX2022014331A (es) 2023-01-04

Family

ID=61159951

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001669A MX2019001669A (es) 2016-08-11 2017-08-10 Metodos y composiciones para el tratamiento de trastornos epilepticos.
MX2022014331A MX2022014331A (es) 2016-08-11 2019-02-08 Metodos y composiciones para el tratamiento de trastornos epilepticos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019001669A MX2019001669A (es) 2016-08-11 2017-08-10 Metodos y composiciones para el tratamiento de trastornos epilepticos.

Country Status (12)

Country Link
US (13) US20180042903A1 (es)
EP (3) EP3586845A1 (es)
JP (3) JP2019524816A (es)
KR (2) KR102518846B1 (es)
CN (1) CN109715151A (es)
AU (2) AU2017311412B2 (es)
BR (1) BR112019002538A2 (es)
CA (1) CA3032686A1 (es)
CO (1) CO2019001193A2 (es)
IL (2) IL264510A (es)
MX (2) MX2019001669A (es)
WO (1) WO2018031748A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
IL305342A (en) 2015-07-17 2023-10-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
KR102408399B1 (ko) 2016-03-08 2022-06-13 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
AU2017311412B2 (en) * 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
SG10202110563YA (en) * 2017-11-10 2021-11-29 Marinus Pharmaceuticals Inc Ganaxolone for use in treating genetic epileptic disoders
JP2022501384A (ja) 2018-09-20 2022-01-06 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics Inc. トゥレット症候群、チックおよび吃音の処置のためのガボキサドールの使用
AU2019377074A1 (en) * 2018-11-05 2021-05-13 Ovid Therapeutics Inc. Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3123876A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
KR20220035195A (ko) * 2019-07-15 2022-03-21 오비드 테라퓨틱스 인크. 치료적 치료를 위한 가복사돌을 포함하는 약학적 제제
WO2021026124A1 (en) * 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
US20230020036A1 (en) * 2019-10-23 2023-01-19 Neurocycle Therapeutics, Inc. Treatment of epileptic conditions with gabaa receptor modulators
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CA3158280A1 (en) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone for use in treating tuberous sclerosis complex
JP2023507764A (ja) 2019-12-18 2023-02-27 オービッド・セラピューティクス・インコーポレイテッド １ｐ３６欠失症候群の治療的処置のためのガボキサドール
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc A canceled gaboxadol ring and its use for the treatment of psychiatric disorders
WO2022125408A1 (en) * 2020-12-07 2022-06-16 Marinus Pharmaceuticals, Inc Use of ganaxolone in treating an epilepsy disorder
EP4412619A1 (en) 2021-10-04 2024-08-14 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
CN114994198B (zh) * 2022-05-20 2023-02-28 上海市精神卫生中心（上海市心理咨询培训中心） 一种液相色谱质谱联用法同时定量检测78种神经精神类药物的方法
WO2024142098A1 (en) * 2022-12-27 2024-07-04 Indian Institute Of Science A method for the treatment of epilepsy

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671750A (en) 1950-09-19 1954-03-09 Merck & Co Inc Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US5340590A (en) 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5391381A (en) 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
EP0391943B1 (de) 1987-11-17 1992-01-02 Robert Bosch Gmbh Verfahren zur korrektur der durch radsensoren ermittelten drehgeschwindigkeit von fahrzeugrädern
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5201756A (en) 1990-06-20 1993-04-13 Danforth Biomedical, Inc. Radially-expandable tubular elements for use in the construction of medical devices
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
CA2112905A1 (en) 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5223265A (en) 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5356476A (en) 1992-06-15 1994-10-18 Materials Research Corporation Semiconductor wafer processing method and apparatus with heat and gas flow control
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US6280771B1 (en) 1997-02-20 2001-08-28 Therics, Inc. Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
WO1995026715A2 (en) 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
WO1995035131A1 (en) 1994-06-22 1995-12-28 Unasco Pty. Ltd. Controlled release device and method
US5556847A (en) 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
JP4484247B2 (ja) 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
US5888996A (en) 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
US5629277A (en) 1995-10-04 1997-05-13 William L. Brown Paint removing composition
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1998057648A1 (en) 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
EP1021172B1 (en) 1997-10-08 2002-04-10 Sepracor, Inc. Dosage form for aerosol administration
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
PL205109B1 (pl) 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6039979A (en) 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6423746B1 (en) 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
JP2003518038A (ja) 1999-12-20 2003-06-03 ニコラス， ジェイ カークホフ， 流動床噴霧乾燥によるナノ粒子製造方法
US6689378B1 (en) 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US8551526B2 (en) 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003030872A2 (en) 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release
UA76810C2 (uk) 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003222027A1 (en) 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
US20040105889A1 (en) 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
AU2003231234A1 (en) 2002-05-03 2003-11-17 Children's Hospital Medical Center Simulated vernix compositions for skin cleansing and other applications
US20040258757A1 (en) 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
SI1542668T1 (sl) 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
US7713551B2 (en) 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
EP1572164A2 (en) 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2005023256A1 (en) 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20050181050A1 (en) 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
BRPI0509210A (pt) 2004-04-02 2007-08-28 Lundbeck & Co As H uso de gaboxadol, e, métodos para tratar função respiratória enfraquecida, e apnéia do sono
US20050226927A1 (en) 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
KR20070121786A (ko) 2005-03-23 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 코르티코스테로이드 및 항히스타민 제제
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
PT2083811T (pt) 2006-11-22 2017-01-23 Clinical Res Ass Llc Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
EP2101735A2 (en) 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
KR100929920B1 (ko) 2007-09-05 2009-12-04 주식회사 마크로케어 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
BR112012003085B1 (pt) 2009-08-13 2021-06-01 Marinus Pharmaceuticals, Inc. Método para obtenção de 3a-hidroxi, 3ss- metil-5a-pregnado-20-ona ( ganaxolona )
ES2646829T3 (es) 2010-01-21 2017-12-18 Drawbridge Pharmaceuticals Pty Ltd. Formulación anestésica
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012075286A2 (en) * 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
CN113956315B (zh) 2011-09-08 2024-08-09 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
WO2014085668A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
TR201808616T4 (tr) 2012-12-18 2018-07-23 Sage Therapeutics Inc Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri.
US20150313913A1 (en) * 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US10202413B2 (en) 2013-02-15 2019-02-12 Washington University Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
MX2015012437A (es) 2013-03-13 2016-04-15 Sage Therapeutics Inc Esteroides neuroactivos, composiciones, y usos de los mismos.
EP3932932A1 (en) 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
HUE041369T2 (hu) 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CA3199003A1 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20170022245A1 (en) 2013-11-26 2017-01-26 Biopharma Works Ganaxolone derivatives for treatment of central nervous systems disorders
US9629853B2 (en) * 2014-05-21 2017-04-25 Wisconsin Alumni Research Foundation Uses of ganaxolone
SG10201803812TA (en) 2014-05-29 2018-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
MX2016016136A (es) 2014-06-06 2017-07-05 Ovid Therapeutics Inc Metodos para incrementar la inhibicion tonica y para tratar insomnio secundario.
US9802945B2 (en) * 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
JP2018504420A (ja) * 2015-02-06 2018-02-15 マリナス ファーマシューティカルズ インコーポレイテッド 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
IL305342A (en) 2015-07-17 2023-10-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US20180235942A1 (en) 2015-08-11 2018-08-23 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
JP6957460B2 (ja) 2015-10-22 2021-11-02 カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． アンジェルマン症候群および関連する障害の処置方法
AU2017311412B2 (en) * 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3528807A4 (en) 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
EP3612186A1 (en) 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations

Also Published As

Publication number Publication date
CO2019001193A2 (es) 2019-02-19
MX2019001669A (es) 2019-09-27
US20180042903A1 (en) 2018-02-15
US20180344708A1 (en) 2018-12-06
US10799485B2 (en) 2020-10-13
EP4233861A2 (en) 2023-08-30
IL304429A (en) 2023-09-01
US11903930B2 (en) 2024-02-20
US20190091209A1 (en) 2019-03-28
US20240066011A1 (en) 2024-02-29
JP2023126947A (ja) 2023-09-12
WO2018031748A1 (en) 2018-02-15
CN109715151A (zh) 2019-05-03
AU2023216824A1 (en) 2023-09-07
JP2019524816A (ja) 2019-09-05
US11395817B2 (en) 2022-07-26
US11806336B2 (en) 2023-11-07
US10363246B1 (en) 2019-07-30
US20190216785A1 (en) 2019-07-18
EP4233861A3 (en) 2023-10-11
US20200179350A1 (en) 2020-06-11
US11918563B1 (en) 2024-03-05
EP3481387A1 (en) 2019-05-15
KR20190038873A (ko) 2019-04-09
AU2017311412B2 (en) 2023-05-18
US20190307733A1 (en) 2019-10-10
EP3586845A1 (en) 2020-01-01
KR102518846B1 (ko) 2023-04-05
JP2022058688A (ja) 2022-04-12
US10603308B2 (en) 2020-03-31
US20230293501A1 (en) 2023-09-21
CA3032686A1 (en) 2018-02-15
US20220362224A1 (en) 2022-11-17
KR20230050474A (ko) 2023-04-14
BR112019002538A2 (pt) 2019-05-21
IL264510A (en) 2019-02-28
EP3481387A4 (en) 2020-04-08
US12109201B2 (en) 2024-10-08
US20230293502A1 (en) 2023-09-21
US20210000805A1 (en) 2021-01-07
AU2017311412A1 (en) 2019-02-07
US20220323424A1 (en) 2022-10-13
US20210213000A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
IL249602A0 (en) Methods and devices for the treatment of posterior ocular disorders
IL266596A (en) Causes, uses and methods of treating synovialitis
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
NZ731467A (en) Anti-tim3 antibodies and methods of use
GB201405232D0 (en) Apparatus and methods for the treatment of ocular disorders
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
PH12019501373A1 (en) Methods of treating cochlears synaptopathy
IL283948A (en) Methods for treating depression
IL272121A (en) Preparation and methods for the treatment of myopia
PH12017500275A1 (en) Methods of treating depression using nmda modulators
IL277805A (en) Use of gaboksadol in the treatment of substance use disorders
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3609578A4 (en) PHARMACEUTICAL COMBINATION AND ITS USE FOR THE TREATMENT OF SYNUCLEINOPATHIES
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
EP3579842A4 (en) 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
EP3436009C0 (en) NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 USEFUL IN THE TREATMENT OF MATURE BRAIN INJURIES
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido